Scientists exploited cytokine-induced killer cells’ expression of FcγRIIIa in combination with clinical-grade monoclonal antibodies to redirect their lytic activity in an antigen-specific manner, and reported the efficacy of this combined approach against TNBC.
[Oncoimmunology]
7992332
{7992332:DEJ77YGZ}
apa
50
1
163515
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
